In Its Third and Final Biosimilar Deal of 2024, Coherus Divests Udenyca

Dec 12
Dec 12, 2024

Coherus BioSciences, Inc. is selling its third and last biosimilar per an agreement to divest its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd. for up to $558.4 million, Coherus revealed on Dec. 3. The granulocyte colony-stimulating factor is one of six biosimilars of Amgen Inc.’s Neulasta (pegfilgrastim). The FDA approved Udenyca on Nov. 2, 2018, making it the second of those agents to gain approval.

Included in the deal, which will give Coherus an upfront cash payment of $483.4 million, are the Udenyca prefilled syringe and autoinjector, as well as the Udenyca Onbody, an on-body injector that Coherus launched earlier this year. Udenyca is the only Neulasta biosimilar with that presentation, which competes with Neulasta Onpro, which has pulled market share from the original subcutaneous formulation.
Read more
© 2025 MMIT

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.